The DDI Marker Studies Knowledgebase has been updated in January 2024, and is available in the DIDB Resource Center.
In this update, 42 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 3 compounds were sensitive substrates, and 3 compounds were strong inhibitors, which could lead to strong drug interactions mediated by CYP1A2, CYP2C19, and CYP3A.
In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.
As always, feel free to contact us if you have any questions or comments.